 |
Allergan Treatments Boyulinum Toxin Type A Injection Skin Care 100iu
Product Details:
| Place of Origin: | China |
| Brand Name: | Allergan |
| Model Number: | 100iu |
Payment & Shipping Terms:
| Minimum Order Quantity: | 2 bottles |
|---|---|
| Price: | usd35/box |
| Packaging Details: | Standard packing. |
| Delivery Time: | 3~5 working days |
| Payment Terms: | T/T, Western Union, PayPal |
| Supply Ability: | 3,000 bottles/week |
|
Detail Information |
|||
| Purity: | 99% | Other Names: | Botulinum Toxin A |
|---|---|---|---|
| Usage: | Skin Care Treatments | Appearance: | White Powder |
| Shelf Life: | 2 Years | Application: | Health-care Products,anti-aging,anti-wrinkle |
| Feature: | Anti-Wrinkle,Anti-aging,Effect | Color: | White |
| Highlight: | Anti Wrinkle Botulinum Toxin Type A,100iu Botulinum Toxin A Injections,Anti Aging Botulinum Toxin A Injections |
||
Product Description
Allergan Treatments Boyulinum Toxin Type A Injection Skin Care 100iu
Indications
Adult Bladder Dysfunction:
Overactive Bladder
for injection is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency in adults who have an inadequate response to or are intolerant of an anticholinergic medication.
Detrusor Overactivity Associated With a Neurologic Condition
is indicated for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition (eg, SCI, MS) in adults who have an inadequate response to or are intolerant of an anticholinergic medication.
Pediatric Detrusor Overactivity Associated With a Neurologic Condition
is indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication.
Chronic Migraine
is indicated for the prophylaxis of headaches in adult patients with Chronic Migraine (≥ 15 days per month with headache lasting 4 hours a day or longer).
Limitations of Use
Safety and effectiveness have not been established for the prophylaxis of episodic migraine (14 headache days or fewer per month) in 7 placebo-controlled studies.
Spasticity
is indicated for the treatment of spasticity in patients 2 years of age and older.
Limitations of Use
has not been shown to improve upper extremity functional abilities or range of motion at a joint affected by a fixed contracture.
Cervical Dystonia
is indicated for the treatment of adults with Cervical Dystonia to reduce the severity of abnormal head position and neck pain associated with Cervical Dystonia.
Blepharospasm and Strabismus
is indicated for the treatment of Strabismus and Blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and older.
Primary Axillary Hyperhidrosis
® is indicated for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents.
Limitations of Use
The safety and effectiveness of for hyperhidrosis in other body areas have not been established. Weakness of hand muscles and blepharoptosis may occur in patients who receive for palmar hyperhidrosis and facial hyperhidrosis, respectively. Patients should be evaluated for potential causes of secondary hyperhidrosis (eg, hyperthyroidism) to avoid symptomatic treatment of hyperhidrosis without the diagnosis and/or treatment of the underlying disease.
